Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?

Decruyenaere A, Christine G, Sylvie R, Annouschka L, Seront E, Everaert E, Debruyne PR, Van Den Bulck H, Bastin J, Annelies V, Vulsteke C, Schatteman P, Luyten D, Aspeslagh S, Martinez-Chanza N, De Bock M, Meyskens T, Verheezen J, Brouwers B, Beuselinck B